We're not going to be disappointed but I also wouldn't expect fireworks in the share price immediately upon the first study result being released. This isn't an FDA phase 3 decision type of study :) It will further advance and prove the xB3 science to the partners we are in discussions with for licensing deals and others that we are in discussions with that haven't yet reached the negotiating phase. As well, those (biotechs, pharmas, interested investors) that are watching from the sidelines will be more inspired as they read out the first, second and third study results over the coming weeks. That will build more credibility for the science and the company which will only be a positive thing moving forward.